Clinical trial

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

NCT03637803

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2019-01-10

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2019-01-10Date precision: day

Registry last updated2023-06-01

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Oncologyunresolved

Solid Tumorunresolved

Non Small Cell Lung Cancerunresolved

Renal Cell Carcinomaunresolved

Melanomaunresolved

Bladder Cancerunresolved

Interventions

Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]DRUG

Sponsors & collaborators

4D pharma plclead sponsor

Merck Sharp & Dohme LLCcollaborator

Mapped research locations

HoustonTexas, United States2 PittsburghPennsylvania, United States1 Kansas CityKansas, United States1 SpokaneWashington, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03637803 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.